Cathrin Petty, co-head of EMEA healthcare at JP Morgan, says the U.K. has the capacity to be a successful market for life sciences, and the year ahead for healthcare IPOs looks strong.» Read More
Medical device maker, Abiomed's CEO, Michael Minogue, discusses his company's earnings beat, and whether the ultra expensive stock, selling for 5.8 times next year's sales, still has room to run, with Mad Money's Jim Cramer.
Physicians are embracing Web-based software solutions that are bringing healthcare services into the home.
A spokesman for the medical-technology industry warned that a new medical-device tax that goes into effect in 2013 under the Obama health-care law could force some companies to cut jobs.
Here is our list of the 15 of the most influential inventions over the past 50 years, created using a variety of studies as reference points, including ones from Knowledge@Wharton and Popular Mechanics.
Though the U.S. had made much progress taking medical record keeping into the digital age, there's still some doubt that the government will reach its target by the prescribed deadline.
The federal government has received a surge in complaints in recent months about failed hip replacements, suggesting that serious problems persist with some types of artificial hips even as researchers scramble to evaluate the health dangers. The New York Times reports.
Blood-testing equipment maker Immucor says it agreed to be acquired by TPG Capital in a deal worth $1.97 billion, or $27 per share in cash.
Ranking No. 1 for the 5th year running, California surpassed even its own 2010 performance. Yet, tech-savvy runners-up to the Silicon Valley state aren’t that far behind.
Making a case for lap-band surgery and discussing the benefits to patients and insurance companies, with David Pyott, Allergan CEO.
A new test developed by a unit of biotech company Life Technologies has shown success in quickly pinpointing the strain of E. coli involved in a European outbreak that has killed 25 people and sickened more than 2,400 worldwide.
While growing computing demand will mean more energy consumption, wider use of cloud computing technology will prove to be a net benefit to the environment over the longer term, say industry watchers.
Rep. Ron Paul (R-TX) outlines his bid for US president. "Why have we given up on the free market?" he says. "What we're doing is destroying the purchasing power of the dollar."
Medtronic, the world's largest medical device maker, says its fourth-quarter net income dropped 19 percent on expenses related to its recent layoffs.
The Centers for Disease Control considers obesity in America an epidemic; more than one out of three adults and 17 percent of all children are technically overweight to the point of obesity.
Spending a month in China earlier this year left me with a clear picture of a nation of rapid change, vast scale, and stark contrasts. All of these factors create opportunities – and challenges – for American businesses in China, and particularly for those of us in health care.
Personalized medicine has finally arrived and is poised to deliver significant health improvement and healthcare cost savings.
The government is making an increasing number of expensive life-saving or life extending drugs and devices available to more people, but is that the right thing to do and can we afford it, anyway?
Health care is an emotional subject for many Americans — and often one of extremes. Yet, as we obssess about the system's structure and cost, we neglect our own health. Obesity and high blood pressure are more common, while exercise and diet are overlooked. Our special report, "Healthy Business", explores these issues.
More and more American women are seeking infertility treatment to increase their chances of having a child, but there's been no change in success rates and costs remain high, even with health insurance coverage.
Expected government cuts to Medicare and Medicaid, the uncertainty of health care reform and looming patent expirations are weighing heavily on the outlook of the biggest companies in the sector: large-cap pharmaceutical stocks.